Alnylam Pharma Loss Wider Than Estimates

(RTTNews) - Alnylam Pharmaceuticals Inc (ALNY) on Thursday reported second-quarter net loss of $71.8 million or $0.85 per share compared with a loss of $44.1 million or $0.58 per share last year.

Revenues for the quarter were $8.7 million compared with $7.3 million in the prior year.

Analysts polled by Thomson Reuters estimated a loss of $0.75 per share on revenues of $12.6 million for the quarter. Analysts' estimates typically exclude special items.

Operating expenses climbed to $81.6 million from $52.3 million a year ago.

Alnylam is a biopharmaceutical company that develops and commercializes novel therapeutics based on RNA interference.